Method for treating gestosis

FIELD: medicine, obstetrics.

SUBSTANCE: the present innovation deals with treating light-degree gestosis. One should perform percutaneous laser irradiation of renal area at pregnancy terms being 30-33 wk at impulse power of 10 W and frequency of impulse sequence of 80 Hz. Laserotherapy course consists of about 7-10 procedures to be carried out daily. The method enables to interrupt gestosis symptomatology after therapy, decrease the risk for the development of severe forms of the present complication at terms of mature pregnancy and necessity in medicinal therapy and, also, achieve better perinatal results, that is, to increase the number of healthy babies born.

EFFECT: higher efficiency of therapy.

2 ex

 

The present invention relates to medicine, namely to obstetrics.

The level of technology

Analogues: a well-known percutaneous techniques of laser therapy in pregnant women for the treatment of intrauterine bacterial infection and bacterial amnionitis (Artemiev V.E., ECCO L.A., 1996, 1997), in treatment-gestational pyelonephritis (Nagorno SCI, 1998, Kurbanov S.D., Hajimetov A.A., Shamirov A.K., 1997), treatment of placental insufficiency (Vasiliev O.A., Cartelised A.V., 1999) laserpuncture treatment for preeclampsia (Gubanova GG, 1984). Percutaneous methods of low-intensity laser (LLLT) was used to influence the microcirculation system, the activation mechanisms of nonspecific immunity and metabolic processes.

Evaluation of detoxification steps used modes of laser therapy was not performed.

The prototype is the technique of intravenous laser irradiation of blood (ILIB) in pregnant women with preeclampsia varying degrees, the main effect of which was the impact on the performance of endotoxemia (Assegnare, 1995). The positive effect of therapy was evaluated according to clinical and laboratory criteria: clinical symptoms and laboratory criteria of endogenous intoxication and antioxidant protection. However, the invasiveness of the technique of laser therapy does not allow IP is to alsowhat it widely.

The invention

The purpose of the invention is to develop a non-invasive technique of laser therapy for the treatment of preeclampsia mild severity to provide a system detoxification effect on the body of the pregnant woman. This goal is achieved by mode of exposure, taking into account the features of the microcirculation of the kidney. Security methods and detoxification effect proved in the previous experimental study on laboratory rats.

The advantage of using a percutaneous technique of laser radiation is the ease of use, security, and non-invasive for the patient.

The method is as follows.

The rate of percutaneous laser therapy (7-10 procedures on the kidneys is carried out in the period of pregnancy 30-33 weeks in patients with preeclampsia mild scale (MOH, 1999), including swollen and edematous-hypertensive form in terms of the Department of pathology of pregnancy obstetric hospital.

Before you begin any of the procedures of pregnant women with mild preeclampsia examined for markers of endotoxemia: the level of the CEC, triglycerides, creatinine, platelets, LEAH, nst-test; conduct an ultrasound of the kidneys pregnant to eliminate anomalies and the presence of urolithiasis, clarification of the status of the fetus by standard methods is am ultrasound scanning and cardiotocography. When urogenital infections undertake the reorganization prior to the laser therapy.

Before the 1st of procedure of taking blood from a peripheral vein for determination of sensitivity to laser exposure based on the methodology developed in the Center of laser medicine on the basis of the clinical hospital №7. The technique based on the determination of the optical density plasma using refractometry, allows you to select individual exposure time for each patient. The plasma of the patient in the amount of 1-2 ml placed in a Petri dish. Using a Refractometer to determine the initial optical density of the plasma. Then carry out the irradiation of the plasma in a Petri dish for 1 minute and determine the value of optical density, each time increasing the exposure duration of 1 minute. Thus, receive the results of optical density plasma during laser exposure for 1, 2, 3 minutes and so on up to 10 minutes. The results recorded in the form of a graph, the exposure time, which is the maximum deviation of the values of optical density plasma from the initial value, is considered optimal for this patient. The total treatment time is divided in half with two locations.

Sessions of laser therapy is carried out in terms of the Cabinet physiotherapy apparatus “Mustang”, model 024 with radiant Ter what Inal MLOC company “Technique” (No. 95/311-211 in the State register of medical products, 1997). The power of low level laser radiation (LLLT) on the end of the light guide set at 10 W, pulse frequency of 80 Hz. The procedure is performed daily (assume a break of no more than 1-2 days) contact stable method in the amount of 7-10 on the course. In the situation of a pregnant woman sitting on the kidneys (T10 - T-L) alternately to the right and left paravertebral lines using emitter type MLOC conduct a session of laser therapy.

In the quality control criteria of treatment efficacy using clinical guidelines for management of women with preeclampsia (blood pressure, urine output, weight and laboratory: leukocyte index of intoxication (LII), leukocyte count, platelet count, triglycerides, β-lipoproteins circulating immune complexes (CIC), NBT-test, factor stimulation of cells. After the complex treatment of patients discharged from hospital with the recommendation of the control appear in a one-day diagnostic hospital at 34-35 weeks and antenatal admission to hospital at 38 weeks.

Examples.

1. The patient T-th, 19 years old, with vegetative-vascular dystonia on hypertonic type during pregnancy was complicated by early-onset preeclampsia. In pregnancy 32 weeks weight gain was 15 kg In the survey identified markers of endogenous intoxication: the level of triglycerides blood 2.04 mmol/l, β-l is poproteins 1164 mg/L.

In the complex therapy of preeclampsia, the course NEELY (7 procedures). Starting with the first treatment, a marked increase in diuresis, weight stabilization, at the completion of treatment edematous syndrome were stopped. Laboratory studies decreased levels of indicators of endotoxemia: triglycerides amounted to 0.94 mmol/l, β-lipoproteins 898 mg/L. further progression of preeclampsia is not marked. The term full-term pregnancy when applying for antenatal hospitalization, the patient remained light the severity of preeclampsia. The blood pressure was within normal values, the need for basic magnesia or routine antihypertensive therapy was not. The patient independently of odoratissimus conveyed in the term girl weighing 3700 grams and height of 50 cm with the assessment by Apgar 8/9 points.

2. Patient R-VA, 31, somatically suffers from hypertension 1 degree. From obstetric history deserves attention complications during a previous pregnancy - pre-eclampsia at term, preterm pregnancy (31-32 weeks), and therefore was undertaken surgical delivery. If this pregnancy was registered early OG-preeclampsia - 24 weeks, which required the appointment of antihypertensive drugs (lomir 7.5 mg per day). In the gestation 30-32 weeks in the complex treatment was conducted for 10 CEA the owls of laser therapy. Upon completion of the course showed stabilization of weight, stopped the symptom of numbness of the fingers”. Laboratory criteria was decreased with LEAH of 1.52 to 1.21, and a decrease in CEC from 48.0 to 31.5 srvc. unit If the patient's uterine scar pregnancy ended in term full-term pregnancy (37-38 weeks) surgery caesarean section in a planned manner by birth weight 3250 grams and height of 50 cm with the assessment by Apgar 8/9 points.

Thus, low-intensity laser irradiation promotes the relief of symptoms of preeclampsia after completing the course of treatments, and also prevents the progression of this complication and the development of severe forms of preeclampsia. Non-invasive technique of laser therapy on the kidneys is effective in the treatment of preeclampsia is mild and safe for the fetus.

Sources of information

1. Artemiev V.E., ECCO L.A. Some peculiarities of the course of infection with infrared laser exposure in pregnant women with bacterial amnionitis//New directions for laser medicine: proceedings of the international conference. - M., 1996. - Pp.118-119.

2. Artemiev V.E., ECCO L.A. Polylysine radiation and immunity in pregnant women with intrauterine infection//Problems of laser medicine: Proceedings of the 4th international Congress. - Prominent, 1997. - S.112-113.

3. Bednarskaya A.S., Chicana, Yaroslavl VK, Daniel L.A., Reznikov L.L. Application of endovascular laser therapy in complex treatment of OPG-gestosis//Akush. and gin. - 1995. No. 5. - P.18-22.

4. Vasiliev O.A., Cartelised AV Therapeutic opportunities of low-intensity laser radiation in pregnancy with placental insufficiency infectious Genesis//Laser and health-99: proceedings of the international Congress. - M., 1999. - S-140.

5. The Gazazian MG, Vasiliev O.A. Influence of low-intensity laser irradiation of blood of pregnant women to the fetus and newborn with placental insufficiency.//Laser medicine. - 2000. No. 4(1) - P.7-11.

6. Gubanova GG, Didia CG, Bakradze WAS the Use of laser beams in obstetrics. - Tbilisi, 1984. - 154 C.

7. Itskovich A.I., Ponomarenko T.N., Aspens YA Laser therapy in neonatology. - Vladivostok: Dalnauka, 1999. - S.

8. Kurbanov S.D., Hajimetov A.A., Shamirov A.K. Influence of low-intensity laser radiation on the performance of KOS in pregnant women with chronic pyelonephritis. The laser and health-97. Materials of the 1st international Congress. Cyprus. - 1997. - P.75.

9. Nagorno V.F., Ivanov A.N. The use of infrared laser radiation in the prevention of late gestosis//Medical rehabilitation, balneology, physiotherapy. - 1998. No. 2 (14). - P.30-32.

10. Peshev L.P., kildishev A.N., Soloviev, H.E., Paramonov AS and other Optimization of therapy of gestosis using transcutaneous laser irradiation of blood. Problems in laser medicine. Materials of the 4th international Congress. Vidnoye. - 1997. - S-131.

Treatment of preeclampsia by the laser, wherein the exposure is carried out in the period 30-33 weeks of gestation on the kidneys by the radiation power at the end of the optical fiber 10 W, pulse frequency of 80 Hz daily for 7-10 days, the exposure time is adjusted individually to the sensitivity to laser exposure.



 

Same patents:

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating cerebral diseases, Parkinson's disease being among them. One should measure biochemical and immunological blood values of a patient, the values of MAO-B thrombocytes activity, the values of erythrocytes activity, Cu/Zn - TFD, the level of neuromediators of glutamate and taurine in blood plasma and circulating immune complexes (CIC) in blood serum. To perform the impact with laser irradiation it is necessary to choose the patients with all, several or only one value in ranges given below: MAO-B 90-250 nM/mg or MAO-B 0-47 nM/mg, at the norm of 73+7 nM/mg, Cu/Zn - TFD 1.2-2.5 U/mg or Cu/Zn - TFD 0-0.8 U/mg, at the norm of 1.5 ± 0.05 U/mg, CIC low-molecular fractions 100-300 c.u., at the norm of 80 ± 5.0 c.u., CIC average-molecular fractions 48-150 c.u., at the norm of 39 ± 2 c.u., affected ratio of glutamate to taurine. Impact should be carried out intravenously with the help of a light guide at the power at its end being 1 mW and wave length of 632.8 daily for 5 d, every seance lasts for 20 min, then medicinal therapy should be fulfilled without laser impact by repeating the course of laser irradiation in a year. The method enables to increase the quality in treating Parkinson's disease due to stimulating the system of antiradical tissue protection, increased protective body reserves and correction of immune disorders.

EFFECT: higher efficiency of therapy.

FIELD: medicine, gynecology, oncology.

SUBSTANCE: the present innovation deals with treating pre-cancer pathology of uterine cervix in women with either bacterial or viral infection. One should affect the tissues of uterine cervix with low-intensity infrared radiation of semiconductor laser at wave length being 0.89 nm, frequency of 80 Hz, power of 6 W. Simultaneously, one should perform hypervenous blood photomodification in projection area of left elbow vein and sternum, per 2.5 min for every area. Hypervenous blood photomodification should be carried out with the help of a matrix emitter MLOK-6. Laser impact should be fulfilled due to application of "Mustang-bio" apparatus, emitting head LO-2 and a gynecological headpiece G-1.

EFFECT: higher efficiency of therapy.

2 cl, 1 ex, 1 tbl

FIELD: medicine, surgery.

SUBSTANCE: one should introduce solution "Rheamberin 1.5%"intravenously with infusomates at the dosage of 5 ml/kg/d during the next 5 d. Then, 1-2 h later, one should infuse intravenously "Dalargin" at 30 mg/kg/d dissolved in 60 ml 0.9% sodium chloride at the rate of 120 ml/h for 5 d. Additionally, 4-5 h after "Dalargin" injection it is necessary to perform daily intravenous He-Ne laser irradiation of blood beginning since the first day at wave length being 0.63 mcm, power 1 mW, exposure 50-60 min, course lasts for 5 d. The method enables to interrupt intestinal paresis in case of vertebral traumas and wounds in earlier terms.

EFFECT: higher efficiency of therapy.

1 ex

FIELD: medicine, gastroenterology.

SUBSTANCE: laser therapy should be prescribed at differentiated mode. In case of primarily detected pathology or disease duration for under 10 years or rarely relapsing form and availability of pronounced pain syndrome cutaneous impact should be performed at wave length of 0.89 mcm, impulse power of 5-7 W, impulse frequency of 80-150 Hz, by contact-stable technique for standard fields of impact, impact time being 64-128 sec/field, about 10-12 procedures/course. In case of disease duration being above 10 years in elderly groups, at pronounced astheno-autonomic syndrome and at no or unpronounced pain syndrome one should conduct intravenous laser impact at wave length of 0.63 mcm, radiation power at the edge of a disposable intravenous light guide being 1-1.5 mW, duration of procedure being 20 min, 7 procedures/course. Combined method deals with daily successive intravenous and cutaneous impact according to the above-mentioned technique - in case of disease duration above 10 years, frequently relapsing form, availability of multiple or combined ulcers and availability of two or more parallel diseases. The method enables to decrease terms of hospitalization, decrease frequency of exacerbations and prolong remission period.

EFFECT: higher efficiency of therapy.

1 dwg, 2 ex, 2 tbl

FIELD: medicine, gynecology.

SUBSTANCE: one should perform surgical destruction of endometrioidal heterotopias, antibioticotherapy followed by hormone-modulating therapy. Moreover, it is necessary to irradiate blood through a monofilamentous quartz light guide introduced into patient's elbow vein with the help of He-Ne laser at wave length being 628 nm at 15 min duration during the first 5 procedures and for 30 min during 2 last procedures followed by prescribing GnRH agonists for 7 d at the background of antibioticotherapy, intake of analgetics and vobenzyme beginning since the 1st postoperative day.

EFFECT: higher efficiency of therapy.

2 ex

FIELD: medicine.

SUBSTANCE: method involves detecting pathological changes and setting diagnosis. Biologically active points corresponding to the disease and points or zones of Zakharyin-Gedda with low electric resistance are determined. Constant action is first applied to them with DC intensity of 1-10 mcA. Electric stimulation intensity is increased to reach sensory response of a patient. Then, magnetic infrared laser therapy is applied.

EFFECT: enhanced effectiveness of treatment; accelerated treatment course.

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-2% aqueous solution of photosensibilizer agent of chlorine series. After accomplishing enucleation, scanning laser radiation of muscle funnel cavity is carried out. Muscle funnel cavity tamponade is done with two implant components. The implant is manufactured from carbon felt impregnated with photosensibilizing gel based on hyaluronic acid viscoelastic. The gel has 0.1-1 % by mass of photosensibilizer of chlorine series. The first implant component is placed at the beginning. Scanning laser radiation of muscle funnel cavity with the first implant component being arranged therein, is carried out during 2-4 min after 15-30 min long exposure away from light action. The second implant component is placed. Scanning laser radiation of muscle funnel cavity after 15-30 min long exposure away from light action is carried out in the same mode. Muscles are sutured. Soft tissues are sutured layer-by-layer. The postoperative space is drained. Sutures are placed on conjunctiva. Eye prosthesis is set and eyelids are sutured to each other. Photosensibilizer agent of chlorine series is repeatedly introduced into cubital vein of one of the arms. 5-15 min later, intravenous laser radiation treatment of blood is carried out via laser light guide introduced into cubital vein of one of the other arm, during 10-45 min with total power of 20-50 mW.

EFFECT: enhanced effectiveness of treatment; excluded soft tissue deformity in orbital region; reduced implant rejection and carcinoma cells metastasis and dissemination risk.

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-1% aqueous solution of photosensibilizer agent of porphyrin or hematoporphyrin series belonging to Photohem or Photophryne group at a dose of 2.5-5.0 mg/kg. After accomplishing enucleation, scanning laser radiation of muscle funnel cavity is carried out. Muscle funnel cavity tamponade is done with two implant components. The implant is manufactured from carbon felt impregnated with photosensibilizing gel based on hyaluronic acid viscoelastic from chealon, viscoate or hyatulon group. The gel has 0.1-1 % by mass of photosensibilizer of porphyrin or hematoporphyrin series belonging to Photohem or Photophryne group. The first implant component is placed at the beginning. Scanning laser radiation of muscle funnel cavity with the first implant component being arranged in it, is carried out during 2-4 min after 15-30 min long exposure away from light action. The second implant component is placed. Scanning laser radiation of muscle funnel cavity after 15-30 min long exposure away from light action is carried out in the same mode. Direct muscles are sutured. Soft tissues are sutured layer-by-layer. The postoperative space is drained. Laser light guide is introduced into cubital vein immediately after enucleation. Intravenous laser radiation treatment of blood is carried out during 10-45 min with total power of 20-50 mW.

EFFECT: enhanced effectiveness of treatment; excluded soft tissue deformity in orbital region; reduced implant rejection and carcinoma cells dissemination risk.

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy, retinotomy, exposing the intraocular neoplasm, surgically removing the intraocular neoplasm, smoothing retina with perfluororganic compound and substituting the perfluororganic compound with silicon oil. After having removed the perfluororganic compound, 10% ozonized Perfluoran emulsion having ozone concentration of 2-4 mg/l is intravenously introduced. Photosensibilizer agent is introduced into cubital vein of the same arm during 5-10 min. Intravenous laser radiation treatment of blood in 5-15 min after beginning photosensibilizer agent injection with wavelength corresponding to maximum light absorption value characteristic of the photosensibilizer agent within 10-45 min under radiation power required for activating photochemical process. Smoothing retina with perfluororganic compound being completed, separating endoscopic laser coagulation of retinotomy region is carried out with diode laser. 1-3 months later, ozonized Perfluoran emulsion, photosensibilizer agent and intravenous laser radiation treatment are repeatedly applied.

EFFECT: enhanced effectiveness of treatment; reduced risk of tumor cell dissemination.

FIELD: medicine.

SUBSTANCE: method involves carrying out vitrectomy with posterior hyaloid membrane and interior boundary membrane in the central retina zone being withdrawn. Vitreal cavity tamponade with perfluororganic compound and retinal endoscopic laser coagulation are carried out. The perfluororganic compound is removed or substituted with physiologic saline or silicon oil in the course of operation. Tunnel is formed in sub-Tenon space after having sealed the eyeball and restored intraocular pressure. Flexible polymer implant covered with hydrogel material is introduced into the tunnel with flat insert manufactured from magnetic material producing permanent magnetic field of 3.5-5 mTesla units with multipolar reversed magnetization. Distal end of the implant having magnetic insert is extrasclerally arranged in the central retina zone edema projection area. The proximal end is sutured to sclera in equatorial zone. 3-5 weeks later, the implant is withdrawn.

EFFECT: enhanced effectiveness of treatment; accelerated retinal edema resorption.

5 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!